CRL-1005 Optivax copolymer data

Vaxcel, a subsidiary of CytRx Corp. (CYTR, Atlanta, Ga.), announced that a Phase I trial has shown safety and adjuvant action of the Optivax copolymer, when given with a beta human chorionic gonadotropin (BhGC) vaccine. Patients with metastatic cancer were given up to three immunizations at monthly intervals, with a fixed dose of the vaccine and adjuvant doses ranging from 3 to 75 mg. The vaccine was supplied by Immuno Therapy Corp. (Seattle, Wash.).

As reported at the meeting of the American Academy of Allergy, Asthma & Immunology, the American Association of Immunologists, and the Clinical Immunology Society in San Francisco, both humoral and cellular responses were stimulated without local or systemic toxicity. ...